SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings
About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年年度股东会会议资料 | 2026-05-07 | Chinese | |
| 2025年度募集资金年度存放、管理与实际使用情况鉴证报告 | 2026-04-20 | Chinese | |
| 关于使用自有闲置资金进行现金管理的公告 | 2026-04-20 | Chinese | |
| 2025年度内部控制审计报告 | 2026-04-20 | Chinese | |
| 《2025年度独立董事述职报告》（侯绪超） | 2026-04-20 | Chinese | |
| 董事、高级管理人员薪酬与考核管理制度 | 2026-04-20 | Chinese |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44269986 | 2025年年度股东会会议资料 | 2026-05-07 | Chinese | ||
| 40072750 | 2025年度募集资金年度存放、管理与实际使用情况鉴证报告 | 2026-04-20 | Chinese | ||
| 40072703 | 关于使用自有闲置资金进行现金管理的公告 | 2026-04-20 | Chinese | ||
| 40072699 | 2025年度内部控制审计报告 | 2026-04-20 | Chinese | ||
| 40072673 | 《2025年度独立董事述职报告》（侯绪超） | 2026-04-20 | Chinese | ||
| 40072665 | 董事、高级管理人员薪酬与考核管理制度 | 2026-04-20 | Chinese | ||
| 40072660 | 国泰海通证券股份有限公司关于上海和元生物技术（集团）股份有限公司2025年度募集资金存放与使用情况的专项核查意见 | 2026-04-20 | Chinese | ||
| 40072653 | 《2025年度独立董事述职报告》（吴丹枫-离任） | 2026-04-20 | Chinese | ||
| 40072643 | 2025年年度报告摘要 | 2026-04-20 | Chinese | ||
| 40072623 | 《2025年度独立董事述职报告》（宋正奇-离任） | 2026-04-20 | Chinese | ||
| 40072615 | 2025年度审计报告 | 2026-04-20 | Chinese | ||
| 40072411 | 2025年年度报告 | 2026-04-20 | Chinese | ||
| 40072408 | 《2025年度独立董事述职报告》（甘丽凝-离任） | 2026-04-20 | Chinese | ||
| 40072399 | 2025年度“提质增效重回报”行动方案的年度评估报告暨2026年度“提质增效重回报”行动方案 | 2026-04-20 | Chinese | ||
| 40072389 | 关于2025年度计提资产减值准备及预计负债的公告 | 2026-04-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58266/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58266 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58266 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58266 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58266}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. (id: 58266)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.